Multiple Milner affiliates recognised at Cambridge Independent Science and Technology Awards
We are delighted that several of our affiliated companies were recognised at the 2023 Cambridge Independent Science & Technology Awards last night. Among the list of awardees was Cardiatec Biosciences, an AI drug target discovery company co-founded by Milner Head...
Dr Cathy Tralau-Stewart appointed Executive Director of the Milner Therapeutics Institute
We are delighted to welcome Dr Cathy Tralau-Stewart as the new Executive Director at the Milner Therapeutics Institute. Cathy will work alongside Director Tony Kouzarides and the Milner team to lead and deliver our vision to transform pioneering science into...
Milner welcomes new Head of Target Discovery
We are delighted to welcome Dr Erica Bello as the new Head of Target Discovery at the Milner Therapeutics Institute. Erica brings to the team broad experience in CRISPR screening and advanced disease models, both from her work at the Wellcome Sanger Institute and more...
Milner Institute collaborates to launch Cambridge AI Club for Biomedicine
The AI Club for Biomedicine, launched earlier this month, is a new initiative created to bring together the biomedical AI and machine learning community in Cambridge. This collaboration between the Milner and CRUK Cambridge Institute will be held on the first Thursday...